Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma

Published:2012-07-09 Issue:1 Volume:54 Page:58-61
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Nayak Lakshmi,Abrey Lauren E.,Drappatz Jan,Gilbert Mark R.,Reardon David A.,Wen Patrick Y.,Prados Michael,Deangelis Lisa M.,Omuro Antonio,

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2012.698736

Reference20 articles.

1. Pharmacotherapy for Primary CNS Lymphoma

2. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma

3. Prospective trial on topotecan salvage therapy in primary CNS lymphoma

4. PCV salvage chemotherapy for recurrent primary CNS lymphoma

5. Temozolomide as salvage treatment in primary brain lymphomas

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR T‐cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real‐life results of the LOC network;American Journal of Hematology;2024-04-08

2. New hopes in relapsed refractory primary central nervous system lymphoma;Current Opinion in Oncology;2023-07-18

3. Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse;Hematological Oncology;2023-06-29

4. EBV and Lymphomagenesis;Cancers;2023-04-04

5. Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis;Neurological Research and Practice;2023-02-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3